Bimekizumab in refractory pityriasis rubra pilaris

J Dtsch Dermatol Ges. 2024 Jan;22(1):102-104. doi: 10.1111/ddg.15252. Epub 2023 Dec 8.

Authors

Christian Kromer¹, Michael P Schön^{1

2}, Rotraut Mössner¹

Affiliations

¹ Department of Dermatology, Venereology, and Allergology, University Medical Center, Göttingen, Germany.
² Lower Saxony Institute of Occupational Dermatology, University Medical Center, Göttingen, Germany.

PMID: 38066410
DOI: 10.1111/ddg.15252

No abstract available

Keywords: IL-17A/F; PRP; bimekizumab; brodalumab; erythrodermia; ixekizumab; secukinumab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Pityriasis Rubra Pilaris* / drug therapy

Substances

bimekizumab
Antibodies, Monoclonal, Humanized